Made by people who have treated the disease

Prof. Miroslav Harjaček, MD, PhD

Successful physician and educator, trained in the USA. He has held various leadership positions, with a proven track record of successfully completing several scientific, technology and business projects.

He currently works as Founder and Executive Chairman of P3 Therapeutics, and as consultant paediatric rheumatologist and Head of the Paediatric Rheumatology Department at Children’s Hospital Srebrnjak, Zagreb, Croatia.

Dario Naletilić, MD

Dario Naletilić is an independent strategy and management consultant with over 30 years of experience in the pharmaceutical industry, advising numerous regional and European companies on business development, leadership and management practices.

Prior to his consultancy career, Dario held various leadership roles at GSK, including European and local positions. He then joined Cipla, leading the start of the company’s European operations. His roles throughout his career include clinical research, medical affairs, commercial operations, business development and general management.

Dario holds a Medical Doctor diploma from the Medical School, University of Zagreb, completed postgraduate study in Leadership and Management of Health Services at the University of Zagreb, and attended doctoral studies in Social Gerontology at Alma Mater Europea in Slovenia. He has continuously attended executive training at INSEAD, MCE, Ashridge Management College and LSE.

Sanda Ročak, PhD

Sanda Ročak is a strategic advisor and interim manager with more than 20 years of experience in biotech and pharmaceutical drug development. Through SAR Consulting, she helps biotech and pharma companies improve the success of their development programs and build stronger, more effective teams.

Before founding SAR Consulting, Sanda held senior leadership roles at uniQure, Galapagos, Shire and Merck Serono. Most recently, at uniQure, she headed Global Program Leadership. Across her career, she has led global programs in neurology, rare diseases, inflammation and fibrosis, through major regulatory submissions, approvals and launches in multiple markets.

Sanda holds a PhD in Molecular and Cell Biology from the University of Zagreb and an Executive Master in Consulting for Change (EMC) from INSEAD. She works in English, French and Croatian.

Patrik Nikolić, MSc

Patrik Nikolić is a medicinal and computational chemist with more than ten years of experience across drug discovery research and the scientific software industry. Through BioRX Partners, he works with preclinical biotech and pharmaceutical companies on compound design and selection, in silico assessment, and independent review of computational chemistry programmes.

Before founding BioRX Partners, Patrik held scientific and commercial roles at Optibrium, Qualia Data Sciences and Fidelta. Most recently, at Optibrium, he was Scientific Strategy Partner, working with discovery teams across the European and APAC markets on predictive modelling and compound prioritisation. Earlier, in translational research at Fidelta, he contributed to published work on the isolation of mononuclear immune cells from human colonic mucosa. He was also scientific advisor to RxDock, an open-source molecular docking project he co-developed.

Patrik holds an MSc in Medicinal Chemistry from the University of Rijeka, awarded summa cum laude, for work on the in silico optimisation of the first DNA-independent mechanism-based inhibitor of DNMT1. He works in Croatian and English.

Prof. Ernest Meštrović, PhD

Ernest Meštrović is Professor of Chemistry and Head of the Department of General and Inorganic Chemistry at the University of Zagreb Faculty of Chemical Engineering and Technology, and President of the Croatian Chemical Society. He brings more than thirty years of experience at the interface of academic research and the pharmaceutical industry, including senior R&D leadership roles at PLIVA, Teva and Xellia Pharmaceuticals, where he headed a 150-person R&D site and directed science and new-technology programmes across international networks.

His scientific expertise covers solid-state chemistry, crystallisation and polymorphism, API process development and the formulation of oral and parenteral dosage forms – the chemistry that turns a promising molecule into a manufacturable medicine. He has led or contributed to the development of more than 40 active pharmaceutical ingredients and is the author of 20+ patents and patent applications, including a crystalline form of azithromycin that was taken into commercial production for the US and European markets. Intellectual property is a central part of his work: he has served on a corporate IP council and advises on patent strategy, freedom-to-operate analysis and the protection of results on the path from laboratory to licensing.

His current research extends these foundations to organ-on-a-chip platforms, printed sensors and data-driven formulation design – tools directly relevant to P3 Therapeutics’ preclinical testing strategy. At P3 Therapeutics he leads proof-of-concept activities, ensuring that each candidate molecule is evaluated with scientific rigour, manufacturability in mind and a clear IP position.